A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2013
At a glance
- Drugs Resveratrol (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 29 Nov 2010 Planned End Date changed from 1 Dec 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 27 Apr 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.